Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa

Epidermolysis bullosa (EB) is a hereditary disease of skin tissues that causes painful bleeding blisters in the skin and mucous membrane. The prevalence of this disease is 1 in 50,000. The severity of the disease varies depending on the type of disease and may even lead to death. This disease is caused by a genetic mutation in keratin or collagen, and its incidence is the same in all men and women of different human races. In these patients, the skin becomes extremely fragile and peels off with the slightest scratch. Many blisters are one of the most obvious symptoms of this disease. The possibility of skin cancer in people suffering from this disease is more than others. Nowadays, the preference of cell therapy methods is to use biological products produced by cells such as extracellular vesicles and mitochondria instead of stem cells. The use of Extracellular vesicles and engineered EVs as messenger carriers can introduce a new treatment method based on cell products for skin regeneration and as an alternative to cell therapy. Therefore, in this study, EV.FV will be applied topically to patients.

NCT Number	NCT07230223
Lead Sponsor	Isfahan University of Medical Sciences
Conditions	Dystrophic Epidermolysis Bullosa, Wound Heal
Enrollment	20 participants
Start Date	2024-01-09
Primary Completion	2025-12-01 (estimated)
Study Completion	2026-12-25 (estimated)
Updated on ClinicalTrials.gov	2025-11-17